Abstract
TP53 mutations in the absence of 17p-deletion correlate with rapid disease progression and poor survival in chronic lymphocytic leukemia (CLL). Herein, we determined the TP53 mutation frequency in 268 newly diagnosed CLL patients from a population-based material. Overall, we detected TP53 mutations in 3.7% of patients (n = 10), where 7/10 cases showed a concomitant 17p-deletion, confirming the high prevalence of TP53 mutation in 17p-deleted patients. Only 3 (1.1%) of the newly diagnosed patients in our cohort thereby carried TP53 mutations without 17p-deletion, a frequency that is much lower than previous reports on referral cohorts (3-6%). Our findings imply that TP53 mutations are rare at CLL onset and instead may arise during disease progression. (C) 2010 Elsevier Ltd. All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 272-274 |
Journal | Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis |
Volume | 35 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2011 |
Bibliographical note
The information about affiliations in this record was updated in December 2015.The record was previously connected to the following departments: Hematology/Transplantation (013022014)
Subject classification (UKÄ)
- Cancer and Oncology
Free keywords
- TP53 mutation
- 17p-deletion
- Prognosis
- Chronic lymphocytic leukemia